Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 8/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819562 | 0.89 | DDB1 (0.58) | DDB1CRBNGPR119MAPTALDH1A1 | |
| SCHEMBL30831013 | 0.83 | DDB1 (0.54) | DDB1CRBNGPR119 | |
| SCHEMBL20437002 | 0.80 | CRBN (0.51) | DDB1CRBNRETALDH1A1 | |
| SCHEMBL20231817 | 0.79 | DDB1 (0.58) | DDB1CRBNGPR119MAPTALDH1A1 | |
| SCHEMBL20423330 | 0.79 | DDB1 (0.56) | DDB1CRBNGPR119MAPTALDH1A1 | |
| SCHEMBL30830804 | 0.79 | DDB1 (0.56) | DDB1CRBNGPR119MAPT | |
| SCHEMBL20231968 | 0.78 | DDB1 (0.54) | DDB1CRBNGPR119MAPT | |
| SCHEMBL26101026 | 0.78 | CRBN (0.54) | DDB1CRBNGPR119MAPTALDH1A1 | |
| SCHEMBL31425804 | 0.78 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL23301226 | 0.77 | DDB1 (0.67) | DDB1CRBNGPR119MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | DDB1 399/4885CRBN 1/4885GPR119 3852/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | DDB1 399/4885CRBN 1/4885GPR119 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.